

AMENDMENTS TO THE CLAIMS

1 – 27. (Cancelled)

28. (Previously Presented) A method of evaluating the effect of a medicine against asthenopia, which comprises the steps of:

- (1) (a) stimulating a ciliary muscle derived from a non-human test animal with a chemical stimulant to induce a first contraction of said ciliary muscle, and washing said ciliary muscle at a point where the contraction reaches a plateau; and
(b) repeating step (a) 3 to 50 times and terminating at a point where said ciliary muscle shows a decrease of $50 \pm 20\%$ in the tension of muscle contraction, thereby producing *in vitro* asthenopia of the ciliary muscle;
- (2) contacting said ciliary muscle with a medicine in the presence of said chemical stimulant, and
- (3) comparing the decrease in the tension of the muscular contraction before and after contact with the medicine.

29. (Previously Presented) The method of Claim 28, wherein said ciliary muscle in step (b) of (1) shows a decrease of $50 \pm 10\%$ in the tension of muscular contraction.

30. (Previously Presented) The method of Claim 28, wherein the chemical stimulant is selected from the group consisting of acetylcholine, serotonin, histamine, muscarine, nicotine and endothelin.

31. (Previously Presented) The method Claim 29, wherein the chemical stimulant is selected from the group consisting of acetylcholine, serotonin, histamine, muscarine, nicotine and endothelin.

32. (Previously Presented) The method of Claim 28, carried out with use of a Magnus apparatus.

33. (Previously Presented) The method of Claim 29, carried out with use of a Magnus apparatus.

34. (Previously Presented) The method of Claim 30, carried out with use of a Magnus apparatus.

35-38. (Cancelled)